Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ADC Therapeutics Q4 Adjusted EPS $(0.97) May Not Be Comparable To $(0.50) Estimate, Sales $16.79M Beat $15.33M Estimate

Author: Benzinga Newsdesk | March 13, 2024 07:02am
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.50) by 94 percent. This is a 1112.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $16.79 million which beat the analyst consensus estimate of $15.33 million by 9.52 percent. This is a 75.94 percent decrease over sales of $69.80 million the same period last year.

Posted In: ADCT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist